Oncolys Biopharma Inc
TSE:4588
Oncolys Biopharma Inc
Cash from Operating Activities
Oncolys Biopharma Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Cash from Operating Activities
-¥1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
GNI Group Ltd
TSE:2160
|
Cash from Operating Activities
¥6.5B
|
CAGR 3-Years
68%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
PeptiDream Inc
TSE:4587
|
Cash from Operating Activities
¥12.4B
|
CAGR 3-Years
93%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Cash from Operating Activities
¥24.1B
|
CAGR 3-Years
36%
|
CAGR 5-Years
26%
|
CAGR 10-Years
27%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Cash from Operating Activities
-¥138.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
S
|
StemRIM Inc
TSE:4599
|
Cash from Operating Activities
¥1.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Oncolys Biopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-1.3B
JPY
Based on the financial report for Dec 31, 2023, Oncolys Biopharma Inc's Cash from Operating Activities amounts to -1.3B JPY.
What is Oncolys Biopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-2%
Over the last year, the Cash from Operating Activities growth was 22%. The average annual Cash from Operating Activities growth rates for Oncolys Biopharma Inc have been 3% over the past three years , -2% over the past five years .